Early vigabatrin augmenting GABA-ergic pathways in post-anoxic status epilepticus (VIGAB-STAT) phase IIa clinical trial study protocol

BACKGROUND: Nearly one in three unconscious cardiac arrest survivors experience post-anoxic status epilepticus (PASE). Historically, PASE has been deemed untreatable resulting in its exclusion from status epilepticus clinical trials. However, emerging reports of survivors achieving functional indepe...

Descripción completa

Detalles Bibliográficos
Autores principales: Maciel, Carolina B., Teixeira, Fernanda J. P., Dickinson, Katie J., Spana, Jessica C., Merck, Lisa H., Rabinstein, Alejandro A., Sergott, Robert, Shan, Guogen, Miao, Guanhong, Peloquin, Charles A., Busl, Katharina M., Hirsch, Lawrence J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785535/
https://www.ncbi.nlm.nih.gov/pubmed/35067230
http://dx.doi.org/10.1186/s42466-022-00168-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785535/
https://www.ncbi.nlm.nih.gov/pubmed/35067230
http://dx.doi.org/10.1186/s42466-022-00168-x

Ejemplares similares